Drug intelligence / Profile preview

EpsilonG1

Development stage: Preclinical
Lead developer: LeafBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

EpsilonG1 is a monoclonal antibody (mAb) currently in preclinical development by Mapp Biopharmaceutical and its commercial arm, LeafBio, for the prophylaxis of Epsilon toxin (ETX) poisoning. ETX is a highly potent pore-forming toxin produced by *Clostridium perfringens* types B and D, which is considered a significant biothreat agent due to its high lethality and potential for aerosolization. EpsilonG1 acts by binding to and neutralizing the toxin, thereby preventing its interaction with host cell receptors and subsequent pore formation that leads to cellular lysis and systemic edema. The program is positioned in the discovery and lead candidate stage within Mapp's anti-toxin pipeline.

Other names: Epsilon toxin mAbETX mAb

Targets

ETX (Clostridium perfringens epsilon toxin)

Beyond the preview

Go deeper on EpsilonG1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpsilonG1.

Explore the full profile